Read More

Abeona Therapeutics Provides Regulatory Update On Pz-cel; CRL Did Not Identify Deficiencies Related To Clinical Efficacy Or Clinical Safety Data In BLA, And No New Clinical Studies Requested By FDA To Support Approval

Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies

ABEO

Read More

Analyst Eyes Papa John’s Comparable Sales Amid Price-Value Concerns, Upgrades Stock To Hold

Stifel's Chris O'Cull shifts stance on Papa John's International to Hold, citing pragmatic near-term outlook. Despite lowering the price target to $60 amidst market turbulence, O'Cull emphasizes the stock's resilience. With -1% domestic comparable sales in Q1, challenges persist, particularly in a fiercely competitive market.

PZZA

Read More

PPG Industries Investors Are Concerned Margin Cycle Turning Lower, Says Analyst

KeyBanc analyst Aleksey Yefremov maintains an optimistic outlook on PPG Industries, despite adjusting the price target to $162 post-first-quarter FY24 results. While Q1 earnings met estimates, sales fell short, yet the analyst foresees a promising trajectory ahead.

PPG